Drugs / GHR-LRX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04522180 | Jan 2021 → Jul 2022 | acromegaly | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GHR-LRX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04522180 ↗ |
| Action | Inhibit | “an Antisense Inhibitor of the Growth Hormone Receptor” NCT04522180 ↗ |
| Modality | Antisense oligonucleotide | “an Antisense Inhibitor of the Growth Hormone Receptor” NCT04522180 ↗ |
| Route | Subcutaneous | “GHR-LRX was administered by SC injection.” NCT04522180 ↗ |